Since 2001, Cellartis has been working globally with industry and academia to develop advanced stem cell products and technologies. They have expertise in stem cell handling, scale up, and differentiation into mature and functional human cells. Cellartis was the first company to bring human embryonic stem cell-derived hepatocytes and cardiomyocytes to the market for use in drug discovery. Their focus is on developing human embryonic stem cells and technology for drug discovery research, toxicity testing, and regenerative medicine.